QUOTE AND NEWS
StreetInsider.com  Mar 22  Comment 
Shoe Carnival, Inc. (NASDAQ: SCVL) 16.9% HIGHER; reported Q4 EPS of $0.24, $0.03 better than the analyst estimate of $0.21. Revenue for the quarter came in at $181.9 million versus the consensus estimate of $181.13 million. Shoe Carnival, Inc....
StreetInsider.com  Mar 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TearLab+%28TEAR%29+Announces+1.37M+Warrant+Exercise/7278301.html for the full story.
Benzinga  Jan 24  Comment 
TearLab Corporation (Nasdaq: TEAR) announced today that, after reviewing and accepting labeling submitted to it by the Company, the U.S. Food and Drug Administration has now granted Waiver categorization under the Clinical Laboratory Improvement...
Forbes  Jan 6  Comment 
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that...
StreetInsider.com  Dec 5  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TearLab+%28TEAR%29+Gets+FDA+CLIA+Waiver+for+Osmolarity+System/6994155.html for the full story.
StreetInsider.com  Aug 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/TearLab+Corp.+%28TEAR%29+Reports+Q2+Loss+of+%240.31/6702164.html for the full story.
StreetInsider.com  Jul 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/TearLab+%28TEAR%29+Files+7.69M+Common+Shelf/6668948.html for the full story.
Benzinga  Jun 24  Comment 
TearLab Corporation (Nasdaq: TEAR) today announced that it has entered into a definitive agreement with certain institutional investors and members of its Board of Directors in connection with a private placement of approximately 3.85 million...
StreetInsider.com  Apr 26  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TearLab+%28TEAR%29+Granted+U.S.+Patent+for+Tear+Biomarket+Analysis/6448139.html for the full story.
Benzinga  Mar 4  Comment 
TearLab Corporation (Nasdaq: TEAR) announced today that it is in receipt of a communication from the U.S. Food and Drug Administration ("FDA") indicating that the data submitted by the Company was not sufficient to gain approval of its CLIA Waiver...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki